Parallax Health Sciences Announces Increased Customer Acquisition in Both Management and Diagnostics Divisions
April 09 2020 - 11:48AM
InvestorsHub NewsWire
Parallax Health Sciences Announces
Increased Customer Acquisition in Both Management and Diagnostics
Divisions
Company Receives Over $10 million of Telehealth
and Medical Supply Contracts from Coast to Coast
NEW YORK, NY -- April 9, 2020 -- InvestorsHub NewsWire
-- Parallax Health Sciences, Inc. (PRLX)
(“Parallax” or the “Company”), an outcome-driven connected
healthcare company, today announced that its Parallax Health
Management and Parallax Diagnostics divisions have added customer
accounts within the U.S. healthcare industry. Contracts from
home healthcare, nursing homes, and doctors offices from multiple
service areas across the United States have increased due to
advancement of the strategies within both its Health Management and
Diagnostics divisions catapulted by the surge in demand for its
Good Health Outcomes™ telehealth platform, and the effect of the
global pandemic of COVID-19’s impact on the Parallax Diagnostics
business.
Nathaniel Bradley, President of Parallax Health Management,
stated, “Our communities across the U.S. are grieving together as
we enter this holiday weekend during this unprecedented time in our
history where we have lost so many and so much is changed and
challenging.” Mr. Bradley went on to say, “Here at home in New York
we are focusing on what we can do to help our community and we are
blessed to have patented technology developed for Telehealth,
diagnostics and behavioral healthcare systems that are second to
none in making a real difference in how we can use data-driven
solutions to respond and learn how to better our future
responses.”
“Our focus recently has been on executing our strategies for
Telehealth using our Good Health Outcomes™ platform for remote
patient monitoring, bringing to market our Immunoassay Diagnostics
Rapid Test for COVID-19 and generating orders for diagnostic kits
and personal protective equipment, (‘PPE’),” stated Paul
Arena, Chief Executive Officer of Parallax Health Sciences, Inc.
Mr. Arena added further, “The Company’s heritage was built
around diagnostics point-of-care and patient monitoring. Our
patented technology provides real value to many people who are
quarantined at home as well as the true heroes, the medical care
professionals who are on the frontlines daily. We are pleased
to report that we have presently received over $10 million of
orders for Telehealth related and Medical Supply contracts we are
in the process of fulfilling and we anticipate that number to grow
significantly in the coming weeks and months.”
About Parallax Diagnostics
Parallax Diagnostics is a bio-medical company and wholly owned
subsidiary of Parallax Health Sciences, Inc. Parallax Diagnostics
owns a line of 26 FDA approved, Point of Care diagnostic tests on a
single platform in the area of infectious disease, cardiac, medical
conditions, drugs of abuse, and pregnancy. Parallax
Diagnostics is developing a novel, handheld diagnostic testing
system that is simple, rapid and elegant, offering the potential to
transform the diagnostic landscape by transitioning critical tests
from the centralized lab directly to the hands of the physician or
clinicians. Our focus is on tests that detect and/or monitor
infectious diseases.
About Parallax Health Management
Parallax Health Management has created the World's only remote
patient care technology platform with patented data driven
outcomes, integrated applied behavioral analytics and true
cognitive artificial intelligence. Our industry first
technology solves one of largest problems through the reduction,
the non-adherence to medical regimens. Medical adherence is a $500
Billion Dollar problem in the U.S. alone.
About Parallax Health Sciences
Parallax Health Sciences is a leading-edge technology,
outcome-driven telehealth company that allows for cost-effective
remote diagnosis, treatment and monitoring of patients through
proprietary platforms of integrated products and services. The
Company's interoperable novel applications provide patients
point-of-care testing and monitoring with information communicated
via internet-based mobile phone applications that are agnostic as
to operating system and are built on highly sophisticated data
analytics. Information is retrieved real-time by physicians who are
monitoring patients with chronic diseases or through biometric
feedback for health-related behavior modification, and is automated
for integration into electronic health records. The Company's
products and offerings capitalize on the digital transformation in
healthcare for improved patient compliance, diagnosis and
treatment, and support healthcare system cost savings and
efficiencies. For more information, please
visit www.parallaxhealthsciences.com or www.parallaxcare.com.
Investor Contact:
Paul Arena, CEO
paul@parallaxcare.com
cell 404-915-8449
SOURCE: Parallax Health Sciences, Inc.
Parallax Health Sciences (CE) (USOTC:PRLX)
Historical Stock Chart
From Apr 2024 to May 2024
Parallax Health Sciences (CE) (USOTC:PRLX)
Historical Stock Chart
From May 2023 to May 2024